Jayson Rieger Biography and Net Worth

Dr. Rieger has over 20 years of experience in leadership roles spanning business development, operations, drug discovery and product development in the life sciences industry. Prior to joining Verrica, Dr. Rieger served as Executive Vice President of PBM Capital Group, LLC. Dr. Rieger also served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, Vice President of Research and Virginia Operations for Clinical Data, Inc. and Vice President of Lead Development at Adenosine Therapeutics, LLC. Dr. Rieger earned a BA in Chemistry from Rollins College, a PhD in Medicinal Chemistry from the University of Virginia and an MBA from the University of Virginia Darden School of Business.

What is Jayson Rieger's net worth?: The estimated net worth of Jayson Rieger is at least $965.31 thousand as of August 17th, 2026. Rieger owns 207,593 shares of Verrica Pharmaceuticals stock worth more than $965,307 as of September 17th. This net worth evaluation does not reflect any other assets that Rieger may own. Learn More about Jayson Rieger's net worth.
How do I contact Jayson Rieger?: The corporate mailing address for Rieger and other Verrica Pharmaceuticals executives is 44 West Gay Street, Suite 400, West Chester, PA. Verrica Pharmaceuticals can also be reached via phone at (484) 453-3300 and via email at [email protected]. Learn More on Jayson Rieger's contact information.
Has Jayson Rieger been buying or selling shares of Verrica Pharmaceuticals?: Within the last three months, Jayson Rieger has bought $24,550.00 of Verrica Pharmaceuticals stock. Most recently, on Monday, August 17th, Jayson Rieger bought 5,000 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $4.91 per share, with a total value of $24,550.00. Following the completion of the transaction, the chief executive officer now directly owns 207,593 shares of the company's stock, valued at $1,019,281.63. Learn More on Jayson Rieger's trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), Jayson Rieger (CEO), Ted White (CEO), and David Zawitz (COO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 9 times. They purchased a total of 4,247,576 shares worth more than $18,017,266.64. The most recent insider tranaction occured on August, 18th when CMO Noah L Rosenberg bought 2,030 shares worth more than $9,987.60. Insiders at Verrica Pharmaceuticals own 52.9% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 8/18/2026.

Jayson Rieger Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/17/2026	Buy	5,000	$4.91	$24,550.00	207,593
11/25/2025	Buy	94,311	$4.24	$399,878.64	182,593

Jayson Rieger Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $4.65

$4.57

$4.79

50 Day Range

MA: $5.25

$4.53

$6.53

2 Week Range

Now: $4.65

$3.28

$9.82

Volume

41,303 shs

Average Volume

93,453 shs

Market Capitalization

$79.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49